We also assessed the changes in in vivo EGFR expression level and glucose metabolism by anti-HER-1 therapy using immuno-PET agents 64Cu-PCTA-cetuximab and 18FDG-PET, respectively, which may provide new strategies in targeted tumor therapy. Here, EGFR is linked to neoplasm.